Clinical Study of Perospirone Hydrochloride Combined with Buspirone in the Treatment of Refractory Schizophrenia
Objective:To investigate the clinical effect of Perospirone Hydrochloride combined with Buspirone in the treatment of refractory schizophrenia.Method:A total of 82 patients with refractory schizophrenia admitted to Fuzhou Third Hospital from June 2021 to December 2022 were divided into two groups according to random number table method.The control group(n=41)was treated with Risperidone combined with Buspirone,and the observation group(n=41)was treated with Perospirone Hydrochloride combined with Buspirone.The total effective rate,total incidence of adverse reactions and positive and negative syndrome scale(PANSS)scores and strategic decision support system(SDSS)scores before and after treatment were compared between the two groups.Result:The total effective rate of treatment in observation group was significantly higher than that in control group,and the total incidence of adverse reactions was significantly lower than that in control group(P<0.05).There were no significant differences in PANSS scores and SDSS scores between the two groups before treatment(P>0.05).After 6 and 12 weeks of treatment,PANSS scores and SDSS scores in observation group were significantly lower than those in control group(P<0.05).Conclusion:Perospirone Hydrochloride combined with Buspirone in the treatment of refractory schizophrenia has good clinical effect and high safety,which can significantly improve the social function of patients.
Perospirone HydrochlorideBuspironeRefractory schizophreniaSocial function
国家科技期刊平台
NSTL
万方数据
